Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian Mitchell

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Journal of Medical Genetics|November 10, 2020
Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utilityEmma Tudini, Aimee L Davidson, Uwe Dressel, et al.
Scientific Reports|June 25, 2013
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick, Richard Morgan, Francesca Launchbury, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 13, 2016
Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFabHongyan Li, Bingjian Feng, Alexander Miron, et al.
Molecular Oncology|February 25, 2014
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsMonique D Topp, Lynne Hartley, Michele Cook, et al.
The Lancet. Oncology|August 9, 2016
Monogenic and polygenic determinants of sarcoma risk: an international genetic studyMandy L Ballinger, David L Goode, Isabelle Ray-Coquard, et al.
Plos One|October 23, 2010
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urineHayley C Whitaker, Zsofia Kote-Jarai, Helen Ross-Adams, et al.
BMJ Open|June 23, 2020
Pathways to a cancer-free future: a protocol for modelled evaluations to minimise the future burden of colorectal cancer in AustraliaEleonora Feletto, Jie-Bin Lew, Joachim Worthington, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
Journal of the National Cancer Institute|August 29, 2015
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian CancerSusan J Ramus, Honglin Song, Ed Dicks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancerFrancisco J Candido-dos-Reis, Honglin Song, Ellen L Goode, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Journal of Medical Genetics|November 10, 2020
Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utilityEmma Tudini, Aimee L Davidson, Uwe Dressel, et al.
Scientific Reports|June 25, 2013
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick, Richard Morgan, Francesca Launchbury, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 13, 2016
Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFabHongyan Li, Bingjian Feng, Alexander Miron, et al.
Molecular Oncology|February 25, 2014
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsMonique D Topp, Lynne Hartley, Michele Cook, et al.
The Lancet. Oncology|August 9, 2016
Monogenic and polygenic determinants of sarcoma risk: an international genetic studyMandy L Ballinger, David L Goode, Isabelle Ray-Coquard, et al.
Plos One|October 23, 2010
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urineHayley C Whitaker, Zsofia Kote-Jarai, Helen Ross-Adams, et al.
BMJ Open|June 23, 2020
Pathways to a cancer-free future: a protocol for modelled evaluations to minimise the future burden of colorectal cancer in AustraliaEleonora Feletto, Jie-Bin Lew, Joachim Worthington, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
Journal of the National Cancer Institute|August 29, 2015
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian CancerSusan J Ramus, Honglin Song, Ed Dicks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancerFrancisco J Candido-dos-Reis, Honglin Song, Ellen L Goode, et al.
Pageof 12